- Home
- RDHL
RDHL
Redhill Biopharma Ltd.
as 04-23-2025 4:00pm EST
| Founded: | 2009 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 430.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.80 - $20.28 | Next Earning Date: | 04-10-2025 |
| Revenue: | $8,042,999 | Revenue Growth: | 23.17% |
| Revenue Growth (this year): | 381.91% | Revenue Growth (next year): | N/A |
Latest Redhill Biopharma Ltd. News
RDHL Breaking Stock News: Dive into RDHL Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
RedHill Biopharma Gets Nasdaq Noncompliance Notice
PR Newswire
6 days ago
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
PR Newswire
8 days ago
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
PR Newswire
14 days ago
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
MT Newswires
a month ago
RedHill Biopharma Plans to File for UK Approval of H.Pylori Treatment
PR Newswire
a month ago
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
PR Newswire
a month ago
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
PR Newswire
2 months ago
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
Compare RDHL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RDHL Redhill Biopharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.